Drugs.com - Clinical Trials

Infant with Carbamoyl Phosphate Synthetase 1 (CPS1) Deficiency First to Successfully Receive Personalized Gene Therapy Treatment

Thursday, May 15, 2025 -- A research team supported by the National Institutes of Health (NIH) has developed and safely delivered a personalized gene editing therapy to treat an infant with a life-threatening, incurable genetic disease. The infant...

May 20, 2025 - 01:30
 0
Infant with Carbamoyl Phosphate Synthetase 1 (CPS1) Deficiency First to Successfully Receive Personalized Gene Therapy Treatment
Thursday, May 15, 2025 -- A research team supported by the National Institutes of Health (NIH) has developed and safely delivered a personalized gene editing therapy to treat an infant with a life-threatening, incurable genetic disease. The infant...
Read More

Tags:

Previous Article

IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain ...

Next Article

Calorie Restrictions, Low-Fat Diets May Reduce Depressive Symptoms

Related Posts

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol Myers Squibb Announces Topline Results from Pha...

May 12, 2025  0

Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC

Johnson & Johnson’s TAR-200 Monotherapy Achieves High D...

May 12, 2025  0

Zepbound (tirzepatide) Showed Superior Weight Loss Over Wegovy (semaglutide) in Complete SURMOUNT-5 Results Published in The New England Journal of Medicine

Zepbound (tirzepatide) Showed Superior Weight Loss Over...

May 12, 2025  0